Daniel Anderson

Dr. Daniel Anderson is a Co-Founder of Verseau and has served as a board member since March 2017. He is a leading researcher in the field of nanotherapeutics and biomaterials.

He is appointed in the Department of Chemical Engineering, the Institute for Medical Engineering and Science, the Koch Institute for Integrative Cancer Research, and the Harvard-MIT Division of Health Science and Technology at MIT. The research done in his laboratory is focused on developing new materials for medicine. He has pioneered the development of smart biomaterials, and his work has led to advances in a range of areas, including medical devices, cell therapy, drug delivery, gene therapy, and material science.

Dan received a B.A. in mathematics and biology from the University of California at Santa Cruz and a Ph.D. in molecular genetics from the University of California at Davis.

Dan’s work has resulted in the publication of over 400 papers, patents, and patent applications. These advances have led to products that have been commercialized or are in clinical development, as well as to the foundation of companies in the pharmaceutical, biotechnology, and consumer product spaces including CRISPR Tx (Nasdaq: CRSP), Living Proof, Sigilon, and Olivo Labs.